{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:10:45Z","timestamp":1771326645295,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Geriatric Pharmacotherapy"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.amjopharm.2011.09.002","type":"journal-article","created":{"date-parts":[[2011,10,16]],"date-time":"2011-10-16T19:32:26Z","timestamp":1318793546000},"page":"405-412","source":"Crossref","is-referenced-by-count":50,"title":["Valproic Acid\u2013Induced Parkinsonism in the Elderly: A Comprehensive Review of the Literature"],"prefix":"10.1016","volume":"9","author":[{"given":"Fade","family":"Mahmoud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh R.","family":"Tampi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjopharm.2011.09.002_bib1","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3122\/jabfm.2007.05.070062","article-title":"Valproate-associated hyperammonemic encephalopathy","volume":"20","author":"Wadzinski","year":"2007","journal-title":"J Am Board Fam Med"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib2","doi-asserted-by":"crossref","first-page":"802121","DOI":"10.1155\/2009\/802121","article-title":"Valproic acid-induced hyperammonemia in the elderly: a review of the literature","volume":"2009","author":"Mittal","year":"2009","journal-title":"Case Report Med"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00004850-200015010-00001","article-title":"Current aspects of valproate in bipolar disorder","volume":"15","author":"Lennkh","year":"2000","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib4","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajgp.10.4.476","article-title":"Valproate-induced hyperammonemia as a cause of altered mental status","volume":"10","author":"Feil","year":"2002","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.amjopharm.2006.12.007","article-title":"Treatments for late-life bipolar disorder","volume":"4","author":"Aziz","year":"2006","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1017\/S1041610207006540","article-title":"Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review","volume":"20","author":"Konovalov","year":"2008","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib7","doi-asserted-by":"crossref","first-page":"392091","DOI":"10.1155\/2009\/392091","article-title":"Valproic acid-induced myoclonus in a demented patient: a case report","volume":"2009","author":"Gardner","year":"2009","journal-title":"Case Report Med"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib8","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/(SICI)1099-1166(199702)12:2<272::AID-GPS561>3.0.CO;2-V","article-title":"Extrapyramidal syndrome due to valproate administration as an adjunct to lithium in an elderly manic patient","volume":"12","author":"Wils","year":"1997","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib9","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1212\/WNL.47.3.626","article-title":"Reversible parkinsonism and cognitive impairment with chronic valproate use","volume":"47","author":"Armon","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib10","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s004150050288","article-title":"Reversible parkinsonism induced by prolonged treatment with valproate","volume":"245","author":"Onofrj","year":"1998","journal-title":"J Neurol"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4088\/JCP.v63n0114a","article-title":"Valproate-induced parkinsonism in a demented elderly patient","volume":"63","author":"Iijima","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib13","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1212\/01.WNL.0000121228.32913.00","article-title":"Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate","volume":"62","author":"Easterford","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-2006-931471","article-title":"Parkinsonism and\/or cognitive impairment with valproic acid therapy: a report of ten cases","volume":"39","author":"Masmoudi","year":"2006","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib15","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1111\/j.1528-1167.2006.00711.x","article-title":"The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy","volume":"47","author":"Ristic","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib16","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1111\/j.1532-5415.2006.00991.x","article-title":"Loss of autonomy related to valproic acid intake","volume":"54","author":"Gaubert","year":"2006","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/jnnp.2006.100222","article-title":"Movement disorders in patients taking anticonvulsants","volume":"78","author":"Zadikoff","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib18","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/mds.21514","article-title":"Diagnosis of parkinsonism in older patients receiving sodium valproate","volume":"22","author":"Macphee","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib19","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1002\/mds.22328","article-title":"Pisa syndrome and parkinsonism secondary to valproic acid in Huntington's disease","volume":"23","author":"Salazar","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib20","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1532-5415.2010.02795.x","article-title":"Reversible rapidly progressive dementia with parkinsonism induced by valproate in a patient with systemic lupus erythematosus","volume":"58","author":"Sleegers","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.clineuro.2010.03.003","article-title":"The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics","volume":"112","author":"Munhoz","year":"2010","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib22","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.1994.03510360044034","article-title":"Efficacy of divalproex vs lithium and placebo in the treatment of mania","volume":"271","author":"Bowden","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib23","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/archpsyc.1991.01810250064008","article-title":"Valproate in the treatment of acute mania","volume":"48","author":"Pope","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib24","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00002826-199310000-00009","article-title":"Parkinsonian syndrome in childhood after sodium valproate administration","volume":"16","author":"Alvarez-Gomez","year":"1993","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ana.410380423","article-title":"Reversible dementia and apparent brain atrophy during valproate therapy","volume":"38","author":"Papazian","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib26","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1528-1157.1994.tb02449.x","article-title":"Reversible valproate-induced extrapyramidal disorders","volume":"35","author":"Sasso","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1528-1157.1986.tb03534.x","article-title":"Reversible valproic acid-induced dementia: a case report","volume":"27","author":"Zaret","year":"1986","journal-title":"Epilepsia"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib28","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00415-005-0835-7","article-title":"Gender and the Parkinson's disease phenotype","volume":"252","author":"Baba","year":"2005","journal-title":"J Neurol"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib29","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nrg1831","article-title":"Genetics of Parkinson disease: paradigm shifts and future prospects","volume":"7","author":"Farrer","year":"2006","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib30","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S1471-4914(03)00020-0","article-title":"Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease","volume":"9","author":"Barzilai","year":"2003","journal-title":"Trends Mol Med"},{"issue":"1 Suppl 1","key":"10.1016\/j.amjopharm.2011.09.002_bib31","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1212\/WNL.62.1_suppl_1.S17","article-title":"The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits","volume":"62","author":"Obeso","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.tins.2003.12.006","article-title":"How does Parkinson's disease begin?","volume":"27","author":"Obeso","year":"2004","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1017\/S0317167100023970","article-title":"Treatment of Parkinson's disease with sodium valproate: clinical, pharmacological, and biochemical observations","volume":"6","author":"Nutt","year":"1979","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib34","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/jnnp.41.8.702","article-title":"Sodium valproate in the treatment of levodopa-induced dyskinesia","volume":"41","author":"Price","year":"1978","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejphar.2006.03.076","article-title":"Cytoprotection by lithium and valproate varies between cell types and cellular stresses","volume":"539","author":"Lai","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib36","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/417292a","article-title":"A common mechanism of action for three mood-stabilizing drugs","volume":"417","author":"Williams","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/373339a0","article-title":"Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain","volume":"373","author":"Beck","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib38","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s12031-008-9166-3","article-title":"Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson's disease","volume":"39","author":"Bahat-Stroomza","year":"2009","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib39","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1523\/JNEUROSCI.21-08-02889.2001","article-title":"Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration","volume":"21","author":"Kirik","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0304-3940(01)02513-7","article-title":"A mutation in the human neurofilament M gene in Parkinson's disease that suggests a role for the cytoskeleton in neuronal degeneration","volume":"322","author":"Lavedan","year":"2002","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib41","doi-asserted-by":"crossref","first-page":"9162","DOI":"10.1523\/JNEUROSCI.23-27-09162.2003","article-title":"Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis","volume":"23","author":"Dou","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib42","doi-asserted-by":"crossref","first-page":"6590","DOI":"10.1523\/JNEUROSCI.5747-03.2004","article-title":"Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis","volume":"24","author":"Hao","year":"2004","journal-title":"J Neurosci"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib43","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1471-4159.2004.02725.x","article-title":"The mood stabilizer valproic acid stimulates GABA neurogenesis from rat forebrain stem cells","volume":"91","author":"Laeng","year":"2004","journal-title":"J Neurochem"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib44","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1126\/science.6308771","article-title":"Lewy bodies of Parkinson's disease contain neurofilament antigens","volume":"221","author":"Goldman","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.brainres.2009.09.051","article-title":"Valproate reversibly reduces neurite outgrowth by human SY5Y neuroblastoma cells","volume":"1302","author":"Qian","year":"2009","journal-title":"Brain Res"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib46","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.molmed.2005.01.001","article-title":"Gene dosage and pathogenesis of Parkinson's disease","volume":"11","author":"Eriksen","year":"2005","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib47","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/07853890510007269","article-title":"Genetics of Parkinson's disease","volume":"37","author":"Morris","year":"2005","journal-title":"Ann Med"},{"issue":"Suppl 12","key":"10.1016\/j.amjopharm.2011.09.002_bib48","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1002\/mds.20538","article-title":"Alpha-synuclein dysfunction in Lewy body diseases","volume":"20","author":"Tofaris","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib49","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1523\/JNEUROSCI.0341-06.2006","article-title":"The role of G-protein-coupled receptor kinase 5 in pathogenesis of sporadic Parkinson's disease","volume":"26","author":"Arawaka","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib50","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1523\/JNEUROSCI.0096-06.2006","article-title":"Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity","volume":"26","author":"Leng","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib51","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/3311","article-title":"Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease","volume":"4","author":"Conway","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib52","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1471-4159.2007.04778.x","article-title":"Alpha-synuclein protects cerebellar granule neurons against 6-hydroxydopamine-induced death","volume":"103","author":"Monti","year":"2007","journal-title":"J Neurochem"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib53","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0896-6273(00)80886-7","article-title":"Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system","volume":"25","author":"Abeliovich","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib54","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0022-510X(83)90174-0","article-title":"Inhibition of oxidative phosphorylation in hepatic and cerebral mitochondria of sodium valproate-treated rats","volume":"61","author":"Rumbach","year":"1983","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib55","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.bbabio.2007.06.007","article-title":"Valproic acid metabolites inhibit dihydrolipoyl dehydrogenase activity leading to impaired 2-oxoglutarate-driven oxidative phosphorylation","volume":"1767","author":"Luis","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib56","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1016\/j.febslet.2008.08.028","article-title":"Pyruvate uptake is inhibited by valproic acid and metabolites in mitochondrial membranes","volume":"582","author":"Aires","year":"2008","journal-title":"FEBS Lett"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib57","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1399-5618.2007.00361.x","article-title":"Chronic treatment of rats with sodium valproate downregulates frontal cortex NF-kappaB DNA binding activity and COX-2 mRNA","volume":"9","author":"Rao","year":"2007","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib58","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1017\/S1461145708009802","article-title":"Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage","volume":"12","author":"Bachmann","year":"2009","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.amjopharm.2011.09.002_bib59","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/jmg.2009.067686","article-title":"The unfolding clinical spectrum of POLG mutations","volume":"46","author":"Blok","year":"2009","journal-title":"J Med Genet"}],"container-title":["The American Journal of Geriatric Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543594611001450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543594611001450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T17:03:17Z","timestamp":1560790997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1543594611001450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S1543594611001450"],"URL":"https:\/\/doi.org\/10.1016\/j.amjopharm.2011.09.002","relation":{},"ISSN":["1543-5946"],"issn-type":[{"value":"1543-5946","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}